Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: voyagertherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/26/2024 | $22.00 | Buy | Guggenheim |
3/19/2024 | $30.00 | Buy | H.C. Wainwright |
3/7/2024 | $16.00 | Buy | Citigroup |
1/2/2024 | $14.00 | Equal Weight → Overweight | Wells Fargo |
5/10/2023 | $18.00 | Buy | Truist |
3/10/2023 | $14.00 | Outperform | Oppenheimer |
11/3/2021 | $5.50 → $4.00 | Neutral | Chardan Capital |
10/7/2021 | $6.00 → $9.00 | Neutral → Outperform | Robert W. Baird |
10/7/2021 | $6.00 → $9.00 | Neutral → Outperform | Baird |
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
S-8 - Voyager Therapeutics, Inc. (0001640266) (Filer)
10-Q - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
10-Q - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
ARS - Voyager Therapeutics, Inc. (0001640266) (Filer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
3 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE:NVS) has agreed to license a novel capsid generated from Voyager's TRACER™ capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022. "Novartis is a global leader in gene therapy, and we view their continued selection of our IV-delivered, blood-brain barrier-penetrant capsids as strong validation of our TRA
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on August 28, 2024, and the restricted stock unit award is
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences: The Wells Fargo 2024 Healthcare Conference, in Boston, including a fireside chat at 1:30 p.m. ET on September 5, 2024The Baird 2024 Global Healthcare Conference, in New York City, including a fireside chat at 1:25 p.m. ET on September 11, 2024 Webcasts of any presentations may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the Company's website fo
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days. About Voyager TherapeuticsVoyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company dedicated to leveraging the power of
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - - Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate - - Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chief Financial Officer - - Strong cash position of $371 million as of June 30, 2024, expected to provide runway through multiple clinical data readouts into 2027 - LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology comp
LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI796eccb31a2e48c9a71f6c41edd5c510. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique
LEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Eric Hall, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Hall of a non-qualified stock option and restricted stock units as an inducement material to Dr. Hall's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on July 22, 2024, and the restricted stock unit award is scheduled
LEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Nathan Jorgensen, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Jorgensen of a non-qualified stock option and restricted stock units as an inducement material to Dr. Jorgensen's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on July 8, 2024, and the restricted stock unit awa
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET. Webcasts of the presentations may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the Company's website for at least 30 days. About Voyager TherapeuticsVoyager Therapeutics, Inc. (NAS
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 price target.
Oppenheimer analyst Jay Olson maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and maintains $18 price target.
Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $10 to $8.
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.45) by 55.56 percent. This is a 106.8 percent decrease over earnings of $2.94 per share from the same period last year. The company reported quarterly sales of $19.516 million which beat the analyst consensus estimate of $9.415 million by 107.29 percent. This is a 87.03 percent decrease over sales of $150.480 million the same period last year.
Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding Preclinical safety and efficacy demonstrated in Alzheimer's disease and ALS gene therapies; low IV doses provided broad CNS biodistribution and robust transduction of key cell types
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13D/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
Guggenheim initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $30.00
Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $16.00
Wells Fargo upgraded Voyager Therapeutics from Equal Weight to Overweight and set a new price target of $14.00
Truist initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $14.00
Chardan Capital reiterated coverage of Voyager Therapeutics with a rating of Neutral and set a new price target of $4.00 from $5.50 previously
Robert W. Baird upgraded Voyager Therapeutics from Neutral to Outperform and set a new price target of $9.00 from $6.00 previously
Baird upgraded Voyager Therapeutics from Neutral to Outperform and set a new price target of $9.00 from $6.00 previously
Compass Point initiated coverage of Voyager Digital with a rating of Buy and set a new price target of $45.00
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - - Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate - - Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chief Financial Officer - - Strong cash position of $371 million as of June 30, 2024, expected to provide runway through multiple clinical data readouts into 2027 - LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology comp
LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI796eccb31a2e48c9a71f6c41edd5c510. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI1f6af80e7a614ca7925cbad2f35a55c6. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call,
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BIe93582a25c24475387f933ce1c5337e3. Upon registration, telephone participants will receive a confirmation email detailing how to join the confere
- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer's disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m. ET today - LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2023 financial and operating results. "Voyager continues to advance our prioritized programs towards the clinic: the initiation of GLP toxicology studies for our anti-tau antibody VY-TAU01 kee
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register in advance here. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique pass
- Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer's disease portfolio - - Executed license agreement with Sangamo for prion disease treatment - - Presented validating preclinical results including increased brain transduction of IV-administered TRACER™ capsids across multiple non-human primate species at ASGCT 2023 - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results. "The introduction today of
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report second quarter 2023 financial and operating results before the market opens on Thursday, August 3, 2023. Subsequently, the Company will host a conference call and webcast at 8:30 a.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register in advance here. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a uni
- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer's disease franchise advances: selected lead candidate for anti-tau antibody program; IND submission on track for first half of 2024; launched tau knock-down gene therapy program - - Data accepted for presentation at ASGCT 2023 validate blood-brain barrier penetration and central nervous system transduction with Voyager's novel, intravenously administered capsids - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, In
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report first quarter 2023 financial and operating results before the market opens on Tuesday, May 9, 2023. Subsequently, the Company will host a conference call and webcast at 8:30 a.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register in advance here. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique pass
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO). Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. She most recently served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc. "Jacqui's breadth of expertise across securities, business development, regulatory, intellectual property, and multiple other legal disciplines makes her a strong addition
PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors. Scangos has decades of experience building and leading biopharmaceutical companies, having previously served as CEO of Exelixis, Inc.; Biogen, Inc.; and most recently Vir Biotechnology, Inc. "George is one of the most accomplished executives in the biotechnology industry, and we are honored to have him join our Board of Directors," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "As Voyage
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc. "Grace is a seasoned leader who has founded and managed multiple biotechnology and healthcare businesses," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "As we continue t
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer (CFO); Todd Carter, Ph.D., as Chief Scientific Officer (CSO); and Trista Morrison as Senior Vice President of Corporate Affairs. "Voyager's newly prioritized pipeline targets neurological diseases with significant unmet need, and we are assembling the team needed to execute," said Al Sandrock, M.D., Ph.D., Chief Executive Officer of Voyager. "Pete's extensive corporate finance experie
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors. Dr. Mackey is a seasoned life science executive with more than thirty years of operational experience highlighted by her tenure as Senior Vice President, Global Research & Development, for Pfizer, Inc. "I am delighted to welcome Catherine to our Board at this pivotal time in Voyager's evolution," said Al Sandrock, M.D., Ph.D., chief executive officer of Voyager. "Her outstanding track record of
Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived capsids Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of tumor burden with vectorized HER2 antibodies; updated data from GBA1, vTau, SOD1 ALS programs also to be presented Executed license option agreement with Novartis for target-specific access to next-generation TRACER™ AAV capsids Appointed Alfred W. Sandrock, Jr., M.D., Ph.D. as Chief Executive Officer and Board Member Cash runway into 2024 CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) --